Clinical Trials, Phase I as Topic
Research News and Information

Monday, November 23, 2009

Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.

18 Oct 2009 OBJECTIVE: To describe the characteristics of children enrolled in treatment trials for neurofibromatosis type 1 (NF1)-related plexiform neurofibroma (PN), PN tumor burden, PN-related complications, and treatment outcomes and to highlight the ... Read more...

Attacking cancer at its root.

16 Sep 2009 This year the Lasker DeBakey Clinical Research Award will be shared by Brian Druker, Nicholas Lydon, and Charles Sawyers for their development of a targeted molecular therapy for treating chronic myeloid leukemia. Their work demonstrated the ability ... Read more...

Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma.

30 Aug 2009 Pitrakinra, a 15-kDa recombinant human interleukin-4 mutein, targets allergic Th2 inflammation by competitively binding to interleukin-4 receptor alpha to interfere with interleukin-4 and interleukin-13 action. The authors characterized pitrakinra ... Read more...

Latest indexed articles for 'Clinical Trials, Phase I as Topic'

These are the very latest articles for this heading:

• Trial renews interest in Chagas' disease. 29 Oct 2009
• Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas. 18 Oct 2009
• Attacking cancer at its root. 16 Sep 2009
• Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. 30 Aug 2009
• Phase I drug combination trial design: walking the tightrope. 22 Aug 2009
• A phase II trial of combined treatment of endoscopic mucosal resection and chemoradiotherapy for clinical stage I esophageal carcinoma: Japan Clinical Oncology Group Study JCOG0508. 22 Aug 2009
• UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. 10 Aug 2009
• Targeting the molecular defect in BRCA-deficient tumors for cancer therapy. 2 Aug 2009
• Project Zero Delay: a process for accelerating the activation of cancer clinical trials. Aug 2009
• Rectal microbicides in development. 30 Jul 2009
• Phase 0 trials: a platform for drug development? 16 Jul 2009
• Oncology's first Phase 0 trial. 5 Jul 2009
• Have we established a stereotactic body radiotherapy regimen for liver metastases? 4 Jul 2009
• Clinical roundtable monograph. Combination therapies for MDS. 29 Jun 2009
• Targeting the insulin-like growth factor receptor. 29 Jun 2009
• The most important news at ASCO 2009. 29 Jun 2009
• A consent form template for phase I oncology trials. 29 Jun 2009
• Reovirus-based therapy for cancer. 29 Jun 2009
• Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. 29 Jun 2009
• Paclitaxel chemotherapy for the treatment of gastric cancer. 25 Jun 2009

See a longer list of these articles.

Technical information about 'Clinical Trials, Phase I as Topic'

Definition: Studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.

Descriptor UI: D017321

Alternative terms: Clinical Trials, Phase I as Topic; Clinical Trials, Phase I; Phase 1 Clinical Trials; Phase I Clinical Trials; Clinical Trials, Phase 1; Evaluation Studies, FDA Phase I; Evaluation Studies, FDA Phase 1; Microdosing Trials, Human; Human Microdosing Trial; Microdosing Trial, Human; Trial, Human Microdosing; Trials, Human Microdosing; Human Microdosing Trials; Drug Evaluation, FDA Phase I as Topic; Drug Evaluation, FDA Phase I; Drug Evaluation, FDA Phase 1;

Related Mesh Headings: Nontherapeutic Human Experimentation;

Allowable Qualifiers: adverse effects; classification; economics; history; instrumentation; methods; mortality; nursing; psychology; standards; trends; utilization; veterinary; statistics & numerical data; contraindications; ethics; legislation & jurisprudence;

Tree Number: E05.318.760.535.200; E05.337.250.200; N05.715.360.775.235.200; N06.850.520.450.535.200;

History Note: 2008(1993)

Technical Notes: for general design, methodology, economics, etc. of phase I clinical trials; a different heading CLINICAL TRIAL, PHASE I is used for reports of a specific phase I clinical trial